Hyperliquid Strategies

Hyperliquid Strategies Net Debt per Share

Net Debt per Share of Hyperliquid Strategies (PURR) as of Oct 30, 2026.

Net Debt per Share

-

Last updated:

Net Debt per Share of Hyperliquid Strategies is 2026 - . Net Debt per Share of Hyperliquid Strategies was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hyperliquid Strategies Stock analysis

What does Hyperliquid Strategies do? Hyperliquid Strategies Inc generates revenue through its subsidiary Sonnet BioTherapeutics Holdings, Inc., which develops oncology-focused biologic drugs. The company accumulates HYPE, the native token of Hyperliquid, a blockchain platform designed for financial applications. Sonnet BioTherapeutics operates in the biotechnology sector with a proprietary drug innovation platform. The firm targets biotech investors and pharmaceutical partners seeking advanced oncology treatments. Hyperliquid Strategies Inc's business model centers on digital asset treasury management, leveraging HYPE token holdings. The company's primary products include biologic drugs developed by Sonnet BioTherapeutics and HYPE token assets. Biotechnology investors and pharmaceutical companies represent key customer segments purchasing these products. The firm focuses on high-performance blockchain infrastructure for financial services through its subsidiary's operations. Hyperliquid Strategies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hyperliquid Strategies stock

On Eulerpool you can find the complete historical development of Net Debt per Share Hyperliquid Strategies since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Hyperliquid Strategies

All Key Metrics — Hyperliquid Strategies